These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28401456)

  • 1. Cardiovascular Complications Associated With Novel Cancer Immunotherapies.
    Jain V; Bahia J; Mohebtash M; Barac A
    Curr Treat Options Cardiovasc Med; 2017 May; 19(5):36. PubMed ID: 28401456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity of immune checkpoint inhibitors.
    Varricchi G; Galdiero MR; Marone G; Criscuolo G; Triassi M; Bonaduce D; Marone G; Tocchetti CG
    ESMO Open; 2017; 2(4):e000247. PubMed ID: 29104763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.
    Jain V; Mohebtash M; Rodrigo ME; Ruiz G; Atkins MB; Barac A
    J Immunother; 2018 Sep; 41(7):332-335. PubMed ID: 29965858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitor-related myocarditis.
    Tajiri K; Aonuma K; Sekine I
    Jpn J Clin Oncol; 2018 Jan; 48(1):7-12. PubMed ID: 29045749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity.
    Zhang JC; Chen WD; Alvarez JB; Jia K; Shi L; Wang Q; Zou N; He K; Zhu H
    Acta Pharmacol Sin; 2018 Nov; 39(11):1693-1698. PubMed ID: 29991709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions:
    Tan S; Day D; Nicholls SJ; Segelov E
    JACC CardioOncol; 2022 Dec; 4(5):579-597. PubMed ID: 36636451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure in cancer: role of checkpoint inhibitors.
    Delgobo M; Frantz S
    J Thorac Dis; 2018 Dec; 10(Suppl 35):S4323-S4334. PubMed ID: 30701100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.
    Zhou YW; Zhu YJ; Wang MN; Xie Y; Chen CY; Zhang T; Xia F; Ding ZY; Liu JY
    Front Pharmacol; 2019; 10():1350. PubMed ID: 31849640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer.
    Al-Obaidi A; Parker NA; Choucair K; Alderson J; Deutsch JM
    Cureus; 2020 May; 12(5):e8093. PubMed ID: 32542148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
    Shalata W; Abu-Salman A; Steckbeck R; Mathew Jacob B; Massalha I; Yakobson A
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug therapy for myocarditis induced by immune checkpoint inhibitors.
    Wu Y; Xu Y; Xu L
    Front Pharmacol; 2023; 14():1161243. PubMed ID: 37305530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.